Cohort plc (AIM:CHRT)
London · Delayed Price · Currency is GBP · Price in GBX 1,264.00
-42.00 (-3.22%)
Aug 15, 2025, 4:35 PM GMT+1
Cohort Revenue
In the fiscal year ending April 30, 2025, Cohort had annual revenue of 270.04M GBP with 33.33% growth. Cohort had revenue of 151.81M in the half year ending April 30, 2025, with 44.24% growth.
Revenue
270.04M
Revenue Growth
+33.33%
P/S Ratio
2.19
Revenue / Employee
180.03K
Employees
1,500
Market Cap
590.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 270.04M | 67.51M | 33.33% |
| Apr 30, 2024 | 202.53M | 19.82M | 10.85% |
| Apr 30, 2023 | 182.71M | 44.95M | 32.63% |
| Apr 30, 2022 | 137.77M | -5.54M | -3.87% |
| Apr 30, 2021 | 143.31M | 12.25M | 9.35% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rolls-Royce Holdings | 19.54B |
| RELX PLC | 9.53B |
| BAE Systems | 27.41B |
| Experian | 5.82B |
| Ashtead Group | 8.09B |
| International Consolidated Airlines Group | 28.53B |
| Halma | 2.25B |
| Rentokil Initial | 5.53B |
Cohort News
- 2 months ago - Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Benzinga
- 6 months ago - Cohort plc: High Growth Aerospace And Defense Play With Steep Valuation - Seeking Alpha
- 6 months ago - Cohort expands global reach Down Under with new acquisition - The Armchair Trader
- 8 months ago - U.S. Global Launches Technology And Aerospace & Defense ETF: Why Its Allocation Makes Sense - Benzinga
- 8 months ago - Half Year 2025 Cohort PLC Earnings Presentation Transcript - GuruFocus
- 8 months ago - Half Year 2025 Cohort PLC Analyst presentation Q&A Transcript - GuruFocus
- 9 months ago - Visa Accelerator Program Africa selects Cohort 3 - Zawya
- 11 months ago - Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients - Benzinga